ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Archives of Disease in Childhood 2005;90:1206-1207; doi:10.1136/adc.2005.077289
Copyright © 2005 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Web-only appendix
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waldron, D L
Right arrow Articles by Gringras, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waldron, D L
Right arrow Articles by Gringras, P

LETTER

Melatonin: prescribing practices and adverse events

D L Waldron1, D Bramble2, P Gringras3

1 Harper House Children’s Services, Radlett, Herts, UK
2 Telford & Wrekin PCT, Longbow House, Harlescott Lane, Shrewsbury, UK
3 The Newcomen Centre, Guy’s Hospital, London, UK

Correspondence to:
Correspondence to:
Dr P Gringras
The Newcomen Centre, Guy’s Hospital, London, UK; paul.gringras@gstt.nhs.uk

Keywords: melatonin; sleep; prescriptions

The first 150 words of the full text of this article appear below.

Melatonin is currently an unlicensed, "named patient only" medicine in the UK, although it is available as a dietary supplement in the United States and over the internet. It is used for a variety of sleep disorders in children who often have neurodevelopmental impairments.1,2 There remains a dearth of robust randomised controlled trials to demonstrate its efficacy, while lack of pharmacokinetic, pharmacodynamics, and toxicology data limits knowledge of therapeutic dose ranges, formulations, and adverse effects.

We carried out an anonymous questionnaire survey to examine prescribing practices of members of the British Association for Community Child Health (BACCH) and the British Academy of Childhood Disability (BACD) (see ADCwebsite: http://www.archdischild.com/supplemental).

From a newsletter circulation reaching an estimated 926 paediatricians, responses to the questionnaire were received from 148 (about 15%) (table 1Go).


View this table:
[in this window]
[in a new window]
 
Table 1  Responses to the questionnaire
 
Of these 98% were currently prescribing, or had prescribed melatonin in the last year; . . . [Full text of this article]




This article has been cited by other articles:


Home page
EDUCATION AND PRACTICEHome page
D. K Mehta
BNF for children: listening and learning
Arch. Dis. Child. Ed. Pract., October 1, 2007; 92(5): ep144 - ep148.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health